Rebiotix focuses on pioneering Microbiota Restoration Therapy, developing biologic drugs that transplant live human-derived microbes to reverse pathogenic processes. Its lead product, RBX2660, is a microbiota suspension being studied as a non-antibiotic treatment for recurrent Clostridium difficile infection. The company is working with the FDA to finalize plans for additional clinical studies needed to secure regulatory approval for RBX2660. Proceeds from the recent financing will support pivotal clinical research to advance RBX2660 toward commercialization, fund R&D on therapeutic products and new indications, and provide general working capital. The company is led by founder, president and CEO Lee Jones and is based in Roseville, MN. To date Rebiotix has raised $30M since inception.

Total raised

$25M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2014